Table E.2.
Variation in sales for 25 countries in 2014 and observed changes from 2011 to 2014 in overall sales and sales of critically important antimicrobials (data (EMA/ESVAC, 2016)
| Range in 2014 (in mg/PCU) | Changes in sales 2011–2014 in individual countries) (in mg/PCU)a | No of countries where sales decreased 2011–2014a | No of countries where sales increased 2011–2014a | |
|---|---|---|---|---|
| Overall sales | 3.1–418.8 | From −62.23 to +82.97 | 14 | 11 |
| Sales of 3rd‐ and 4th‐generation cephalosporins | 0.0004–0.79 | From −0.2 to +0.62 | 10 | 15 |
| Sales of fluoroquinolones | 0.004–11.38 | From −3.17 to +2.99 | 11 | 14 |
| Sales of all quinolones | 0.004–11.55 | From −4.24 to +5.49 | 14 | 11 |
| Sales of polymyxinsb | 0.06–36.1 | From −2.67 to +9.67 | 13 | 9 |
Corrections in sales data and/or PCU data published in 2012 are described in Chapter 1.5 of the seventh ESVAC report.
PCU: population correction unit.
a
Only countries for which 2011–2014 data are available are included.
b
For polymyxins data is from 22 countries as polymyxins were not sold in three countries reporting in 2011–2014.